Remove

Under the Paperwork Reduction Act of 1995, no persons are required

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10535187	
Filing Date		2005-10-31	
First Named Inventor	Dharr	maraj Ramachandra RAO et al	
Art Unit		1626	
Examiner Name	S. Young		
Attorney Docket Number		TPP31767	

					0.5.	PAIENIS			WEITHOVE	
Examiner Cite   Patent Number   Kind Code		Kind Code <sup>1</sup>			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1									
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.	_	Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva	s,Columns,Lines whe ant Passages or Rele s Appear	
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	please click the Ad	d buttor	n. Add	
				FOREIG	SN PAT	TENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Relevar Figures Appear	70
	1	2003087050	wo			2003-10-23	LES LABORATORI SERVIER	RES		
	2	1647547	EP			2006-19-04	Diagen Smartno p Ljubljani, d.o.o.	n		
	3	2001122780	JP			2001-08-05	DAI ICHI SEIYAKI LTD.	100		

U.S.PATENTS

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10535187	
Filing Date		2005-10-31	
First Named Inventor	Dhan	maraj Ramachandra RAO et al	
Art Unit		1626	
Examiner Name	S. Young		
Attorney Docket Number		TPP31767	

	NON-PATENT LITERATURE DOCUMENTS Remo	ve			
xaminor (itials* No [block, magazine, journal, serial symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/circ country where published.					
1	PARTIAL EUROPEAN SEARCH REPORT dated July 5, 2006 from corresponding European Patent Ap 06 07 6083.2.	plication No.			
2					
3	PERINDOPRIL (\$ 9490) AND PERINDOPRILATE (\$ 9780)*, DRUG DESIGN AND DISCOVERY, HAR	WOOD			
4	converting enzyme", JOURNAL OF CHROMATOGRAPHY, ELSEVIER SCIENCE PUBLISHERS B.V. A	AMSTERDAM,			
to ad	dd additional non-patent literature document citation information please click the Add button	Add	_		
	EXAMINER SIGNATURE		_		
Signa	ature Date Considered		_		
	1 1 2 2 3 4 4 to ac	Include name of the author (in CAPITAL LETTERS), title of the arride (when appropriate), title (lock, magazine, journal, sorial, symposium, catalog, etc.), date, pages(s), volume-issue num publisher, orly ander county where published.  PARTIAL EUROPEAN SEARCH REPORT dated July 3, 2006 from corresponding European Patent Are 06 to 6832.  VINCENT METAL., "Stenoselective Synthesis of a New Perhydicidoble Derivative of Chris Iminodal inhibitor of Agotenian Converting European," ETRAMEDON, ELSPVERS SCIENCE PUBLISHERS, AIN, N., vol. 23, no. 16, 1982, pages 1677–1690, XP000155080, ISSN: 0004-000, "the whole document."  VINCENT METAL., "Synthesis AND ACE INHIBITIONY ACTIVITY OF THE STEREOSOMERS OF PERINDOPHIL (S 4490) AND PERIODOPHILA (S 450), PAGE STEREOSOMERS OF PERIODOPHIL (S 4490) AND PERIODOPHILA (S 450), PAGE STEREOSOMERS OF ACACHING PUBLISHERS GIBBLY, XV, vol. 9, no. 1, 1982, pages 1573, XP000095076, ISSN: 105-54 and Charles and C	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (took, magazine, journal, serial, symposium, catalog, etc), date, pages (s), volume-issue number(s), publisher, oil yardior county where published.  PARTIAL EUROPEAN SEARCH REPORT dated July 5, 2006 from corresponding European Patient Application No. 06 for 683 2.  VINCENT METAL. "Stereoselective Synthesis of a New Perhydroinoloe Derivative of Christ Immodiacid, a Potent Inhibitor of Applerans Conventing Enzyme", TETRAHEDION, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 23, no. 16, 1982, pages 1677-1690, 27000115090, ISSN 0004-4000, "the vehicle document".  VINCENT METAL. "SYNTHESIS AND ACE INHIBITIONY ACTIVITY OF THE STEREONOMERS OF PERINDOPERILS (SAMP) AND PERINDOPERILATE (SF790), DRUG DESIGN AND DISCOVERY, HARMYOOD ACADEMIC PUBLISHERS (AMBH, XX, vol. 9, no. 1, 1992, pages 127-128, XYR000859976, ISSN: 1055-6912, "page 181-4".  HILLARTS SET AL. "Optimization of capitally electropes separation of several inhibitor of Amsterdam Control of Con		

See Kins Codes of USPTO Patent Documents at sever USPTO\_GOLY or MPEP 901.04. \* Enter of tice that issued the document, by the two-left or gold or WIPO Standard S13... \* For Laprantee patent counters, the ancidator on the year of the region of the Emport or many process or the patent document. \* Kind of counters by the appropriate symbols as andicated on the document under WIPO Standard S11.6 if possible. \* Applicant is to place a check mark here if Emploit insurance instruction as attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10535187		
	Filing Date First Named Inventor Dham		2005-10-31		
			maraj Ramachandra RAO et al.		
	Art Unit		1626		
	Examiner Name S. Yo Attorney Docket Number		xing		
			TPP31767		

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication [7] from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(a)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Thomas P Pavelko/	Date (YYYY-MM-DD)	2006-08-07
Name/Drint	Thomas D. Davelles	Desistration Number	21600

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, V.3.231.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.